Navigation Links
Blood vessels might predict prostate cancer behavior
Date:11/3/2009

COLUMBUS, Ohio A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

The answer may lie in the size and shape of the blood vessels that are visible within the cancer, according to research led by investigators at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in collaboration with the Harvard School of Public Health.

The study of 572 men with localized prostate cancer indicates that aggressive or lethal prostate cancers tend to have blood vessels that are small, irregular and primitive in cross-section, while slow-growing or indolent tumors have blood vessels that look more normal.

The findings were published Oct. 26 in the Journal of Clinical Oncology.

"It's as if aggressive prostate cancers are growing faster and their blood vessels never fully mature," says study leader Dr. Steven Clinton, professor of medicine and a medical oncologist and prostate cancer specialist at Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"Prostate cancer is very heterogeneous, and we need better tools to predict whether a patient has a prostate cancer that is aggressive, fairly average or indolent in its behavior so that we can better define a course of treatment surgery, chemotherapy, radiotherapy, hormonal therapy, or potentially new drugs that target blood vessels that is specific for each person's type of cancer," Clinton says.

"Similarly, if we can better determine at the time of biopsy or prostatectomy who is going to relapse, we can start treatment earlier, when the chance for a cure may be better."

Prostate cancer is the most common cancer in men and the second leading cause of cancer death in American men.

This study analyzed tumor samples and clinical outcome data from men participating in the Health Professionals Follow-Up Study, which involves 51,529 male North American dentists, optometrists, podiatrists, pharmacists and veterinarians.

After an average follow-up of 10 years, 44 of the 572 men had developed metastatic cancer or died of their cancer.

Men whose tumors had smaller vessel diameters were six times more likely to have aggressive tumors and die of their disease, and those with the most irregularly shaped vessels were 17 times more likely to develop lethal prostate cancer.

The findings were independent of Gleason score, a widely used predictor of prognosis based on a prostate tumor's microscopic appearance, and of prostate specific antigen (PSA) level, a blood test used to identify the presence of prostate cancer.

These findings currently apply to men with local disease, whose PSA is only modestly elevated, and who are younger and more likely to choose surgery.

"If our findings are validated by larger studies, particularly in biopsy specimens, the measurement of tumor blood vessel architecture might help determine the choice of therapy, with the goal of improving long-term survival."


'/>"/>

Contact: Doug Flowers
Doug.Flowers@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. High Blood Pressure Likely in Alzheimers Offspring
2. Community Blood Drives Benefit Cancer Patients
3. Fructose May Raise Blood Pressure
4. Central Blood Bank Offers Twilight Fans a way to be Among First to see the Highly Anticipated Sequel New Moon
5. LABS Inc. to Offer Donor Testing Services for Transfusion Medicine and Blood Services Industry
6. Adding Drug Doesnt Help Control Blood Pressure
7. Canadian scientists link fat hormone to death from potentially deadly blood infection
8. Blood Protein May Predict Heart Attack But Not Stroke
9. Cost effectiveness of blood pressure device evaluated
10. New data showed type 2 diabetes patients experienced greater blood sugar reductions
11. Severe Swine Flu Could Lead to Blood Clots in Lungs: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Bay, Jamaica (PRWEB) , ... April 30, 2016 ... ... University, and Duane Boise, President and CEO of EMED, today signed a multifaceted ... Jamaica. , EMED and the Northern Caribbean University Department of Natural and Applied ...
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
Breaking Medicine Technology: